Angelini Ventures Logo clear background.png
Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines
March 21, 2024 03:00 ET | Angelini Ventures
Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing roundFinancing will enable Nouscom to continue advancing the clinical development of...